Contact
Please use this form to send email to PR contact of this press release:
BioFactura’s Biosimilar Ustekinumab, Demonstrates Pharmacokinetic (PK) Bioequivalence to Stelara® in Phase 1 Study
TO:
Jeffrey Hausfeld MD,MBA
BioFactura, Inc.
+1 301-792-8601